BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34634224)

  • 1. Association of body composition with toxicity to first-line chemotherapy and three-year survival in women with ovarian adenocarcinoma.
    Bruno KA; Sobreira da Silva MJ; Chaves GV
    Acta Oncol; 2021 Dec; 60(12):1611-1620. PubMed ID: 34634224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between body composition, survival, and toxicity in advanced esophagogastric cancer patients receiving palliative chemotherapy.
    Dijksterhuis WPM; Pruijt MJ; van der Woude SO; Klaassen R; Kurk SA; van Oijen MGH; van Laarhoven HWM
    J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):199-206. PubMed ID: 30666831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skeletal Muscle Measures as Predictors of Toxicity, Hospitalization, and Survival in Patients with Metastatic Breast Cancer Receiving Taxane-Based Chemotherapy.
    Shachar SS; Deal AM; Weinberg M; Nyrop KA; Williams GR; Nishijima TF; Benbow JM; Muss HB
    Clin Cancer Res; 2017 Feb; 23(3):658-665. PubMed ID: 27489287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
    Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
    J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
    Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
    J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer.
    Aleixo GFP; Shachar SS; Deal AM; Nyrop KA; Muss HB; Chen YT; Yu H; Williams GR
    Breast Cancer Res Treat; 2020 Aug; 182(3):631-642. PubMed ID: 32519169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of body composition on treatment in ovarian cancer: a current insight.
    McSharry V; Glennon K; Mullee A; Brennan D
    Expert Rev Clin Pharmacol; 2021 Sep; 14(9):1065-1074. PubMed ID: 34080491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of muscle measurement using the standardized phase of computed tomography in patients with advanced ovarian cancer.
    Huang CY; Sun FJ; Lee J
    Nutrition; 2020 Apr; 72():110642. PubMed ID: 31986319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
    Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
    Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in skeletal muscle and adipose tissue during cytotoxic chemotherapy for testicular germ cell carcinoma and associations with adverse events.
    Phuong A; Marquardt JP; O'Malley R; Holt SK; Laidlaw G; Eagle Z; Ngo S; Orcutt D; Schade GR; Lin DW; Schweizer MT; Yezefski T; Yu EY; Montgomery B; Grivas P; Fintelmann FJ; Psutka SP
    Urol Oncol; 2022 Oct; 40(10):456.e19-456.e30. PubMed ID: 36028450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association between low skeletal muscle mass and low skeletal muscle radiodensity with functional impairment, systemic inflammation, and reduced survival in patients with incurable cancer.
    Calixto-Lima L; Wiegert EVM; Oliveira LC; Chaves GV; Bezerra FF; Avesani CM
    JPEN J Parenter Enteral Nutr; 2023 Feb; 47(2):265-275. PubMed ID: 36325962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Skeletal muscle radiodensity and visceral adipose tissue index are associated with survival in renal cell cancer - A multicenter population-based cohort study.
    Maurits JSF; Sedelaar JPM; Mulders PFA; Aben KKH; Kiemeney LALM; Vrieling A
    Clin Nutr; 2022 Jan; 41(1):131-143. PubMed ID: 34872047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with variability in skeletal muscle radiodensity in patients with metastatic cancer.
    Calixto-Lima L; Wiegert EVM; de Oliveira LC; Chaves GV; Avesani CM; Bezerra FF
    Nutrition; 2024 Apr; 120():112351. PubMed ID: 38330891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between body composition and chemotherapy-related toxicity in children with lymphoma and rhabdomyosarcoma.
    Wadhwa A; Adams KM; Dai C; Richman JS; McDonald AM; Williams GR; Bhatia S
    Cancer; 2022 Mar; 128(6):1302-1311. PubMed ID: 34847257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Body Composition in Relation to Clinical Outcomes in Renal Cell Cancer: A Systematic Review and Meta-analysis.
    Vrieling A; Kampman E; Knijnenburg NC; Mulders PF; Sedelaar JPM; Baracos VE; Kiemeney LA
    Eur Urol Focus; 2018 Apr; 4(3):420-434. PubMed ID: 28753824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel body composition risk score (B-Score) and overall survival among patients with nonmetastatic breast cancer.
    Cheng E; Caan BJ; Chen WY; Prado CM; Cespedes Feliciano EM
    Clin Nutr; 2024 Apr; 43(4):981-987. PubMed ID: 38471402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low subcutaneous adiposity associates with higher mortality in female patients with cirrhosis.
    Ebadi M; Tandon P; Moctezuma-Velazquez C; Ghosh S; Baracos VE; Mazurak VC; Montano-Loza AJ
    J Hepatol; 2018 Sep; 69(3):608-616. PubMed ID: 29709682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy.
    Guo J; Cai P; Li P; Cao C; Zhou J; Dong L; Yang Y; Xuan Q; Wang J; Zhang Q
    Curr Oncol; 2021 Mar; 28(2):1325-1337. PubMed ID: 33806839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy.
    Ueno A; Yamaguchi K; Sudo M; Imai S
    Support Care Cancer; 2020 Sep; 28(9):4249-4254. PubMed ID: 31900607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.
    Cushen SJ; Power DG; Murphy KP; McDermott R; Griffin BT; Lim M; Daly L; MacEneaney P; O' Sullivan K; Prado CM; Ryan AM
    Clin Nutr ESPEN; 2016 Jun; 13():e39-e45. PubMed ID: 28531567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.